CD274 and melanoma: Clinical evidence that this state of anergy might be reverted when antagonizing the PD-1-PD-L1 axis has been shown in several phase III clinical trials testing anti-PD-1 or anti-PD-L1 antibodies in melanoma or non-small cell lung cancer (27–31).